An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.
Antipsychotics
Mixed methods
Psychosis
Schizophrenia
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
15 03 2022
15 03 2022
Historique:
received:
13
11
2021
accepted:
22
02
2022
entrez:
16
3
2022
pubmed:
17
3
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Antipsychotic medication can reduce psychotic symptoms and risk of relapse in people with schizophrenia and related disorders, but it is not always effective and adverse effects can be significant. We know little of patients' views about continuing or discontinuing antipsychotic treatment. To explore the views of people with schizophrenia and other psychotic disorders about continuing their antipsychotic medication or attempting to reduce or discontinue this medication with clinical support. We collected quantitative and qualitative data by conducting semi-structured interviews in London, UK. Factors predicting a desire to discontinue medication were explored. Content analysis of qualitative data was undertaken. We interviewed 269 participants. 33% (95% CI, 27 to 39%) were content with taking long-term antipsychotic medication. Others reported they took it reluctantly (19%), accepted it on a temporary basis (24%) or actively disliked it (18%). 31% (95% CI, 25 to 37%) said they would like to try to stop medication with professional support, and 45% (95% CI, 39 to 51%) wanted the opportunity to reduce medication. People who wanted to discontinue had more negative attitudes towards the medication but were otherwise similar to other participants. Wanting to stop or reduce medication was motivated mainly by adverse effects and health concerns. Professional support was identified as potentially helpful to achieve reduction. This large study reveals that patients are commonly unhappy about the idea of taking antipsychotics on a continuing or life-long basis. Professional support for people who want to try to reduce or stop medication is valued.
Sections du résumé
BACKGROUND
Antipsychotic medication can reduce psychotic symptoms and risk of relapse in people with schizophrenia and related disorders, but it is not always effective and adverse effects can be significant. We know little of patients' views about continuing or discontinuing antipsychotic treatment.
AIMS
To explore the views of people with schizophrenia and other psychotic disorders about continuing their antipsychotic medication or attempting to reduce or discontinue this medication with clinical support.
METHODS
We collected quantitative and qualitative data by conducting semi-structured interviews in London, UK. Factors predicting a desire to discontinue medication were explored. Content analysis of qualitative data was undertaken.
RESULTS
We interviewed 269 participants. 33% (95% CI, 27 to 39%) were content with taking long-term antipsychotic medication. Others reported they took it reluctantly (19%), accepted it on a temporary basis (24%) or actively disliked it (18%). 31% (95% CI, 25 to 37%) said they would like to try to stop medication with professional support, and 45% (95% CI, 39 to 51%) wanted the opportunity to reduce medication. People who wanted to discontinue had more negative attitudes towards the medication but were otherwise similar to other participants. Wanting to stop or reduce medication was motivated mainly by adverse effects and health concerns. Professional support was identified as potentially helpful to achieve reduction.
CONCLUSIONS
This large study reveals that patients are commonly unhappy about the idea of taking antipsychotics on a continuing or life-long basis. Professional support for people who want to try to reduce or stop medication is valued.
Identifiants
pubmed: 35291964
doi: 10.1186/s12888-022-03822-5
pii: 10.1186/s12888-022-03822-5
pmc: PMC8925064
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
185Informations de copyright
© 2022. The Author(s).
Références
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Arch Gen Psychiatry. 1997 Jan;54(1):49-55
pubmed: 9006400
Acta Psychiatr Scand. 2006 Jul;114(1):3-13
pubmed: 16774655
Psychother Psychosom. 2017;86(4):189-219
pubmed: 28647739
J Clin Psychiatry. 2002 Oct;63(10):892-909
pubmed: 12416599
Schizophr Res. 2020 Nov;225:15-30
pubmed: 31126806
Psychol Med. 2014 Oct;44(14):3007-16
pubmed: 25066792
Schizophr Res. 2020 Jan;215:8-16
pubmed: 31784340
Schizophr Res. 2020 Nov;225:39-46
pubmed: 32115315
J Ment Health. 2018 Aug;27(4):322-328
pubmed: 28857636
Lancet Psychiatry. 2021 Jul;8(7):555-557
pubmed: 33930316
Ther Adv Psychopharmacol. 2019 Apr 08;9:2045125319836566
pubmed: 31007894
Eur Psychiatry. 2016 Aug;36:7-14
pubmed: 27311102
PLoS Med. 2015 Aug 04;12(8):e1001861
pubmed: 26241954
Acta Psychiatr Scand. 2009 Aug;120(2):102-11
pubmed: 19222405
J Ment Health. 2020 Oct;29(5):513-523
pubmed: 30862219
Schizophr Bull. 2021 Jul 8;47(4):1116-1129
pubmed: 33754644
BMC Psychiatry. 2020 Jul 6;20(1):354
pubmed: 32631362
Psychol Med. 1983 Feb;13(1):177-83
pubmed: 6133297
Arch Gen Psychiatry. 2007 Feb;64(2):242-9
pubmed: 17283292
J Affect Disord. 2009 Jul;116(1-2):51-5
pubmed: 19101038
Drug Saf. 2000 Sep;23(3):215-28
pubmed: 11005704
Cochrane Database Syst Rev. 2012 May 16;(5):CD008016
pubmed: 22592725
J Clin Psychiatry. 2006 Oct;67(10):1542-50
pubmed: 17107245
Acta Psychiatr Scand. 2009 Jan;119(1):78-84
pubmed: 18983630
Lancet Psychiatry. 2018 May;5(5):384-386
pubmed: 29699735
PLoS One. 2019 Jun 20;14(6):e0218711
pubmed: 31220160
Issues Ment Health Nurs. 2016 Jun;37(6):400-5
pubmed: 27054268
J Clin Psychiatry. 2013 Nov;74(11):1108-20
pubmed: 24330898
Schizophr Res. 2017 Apr;182:42-48
pubmed: 28277310
Am J Psychiatry. 2017 Oct 1;174(10):927-942
pubmed: 28541090
Soc Psychiatry Psychiatr Epidemiol. 2020 Feb;55(2):151-164
pubmed: 31875238
Qual Health Res. 2017 Mar;27(4):559-572
pubmed: 26984364
Am J Psychiatry. 2017 Jul 1;174(7):686-694
pubmed: 28103712
Health Care Women Int. 1992 Jul-Sep;13(3):313-21
pubmed: 1399871
BMJ Open. 2019 Nov 27;9(11):e030912
pubmed: 31780589
Lancet Psychiatry. 2018 May;5(5):432-442
pubmed: 29551618
CNS Drugs. 2013 Jul;27(7):545-72
pubmed: 23821039
Psychol Med. 2019 Apr;49(5):750-753
pubmed: 30563582
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Patient Prefer Adherence. 2020 Oct 28;14:2043-2054
pubmed: 33149559
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
Psychol Med. 2001 Apr;31(3):509-17
pubmed: 11305859
Chronic Illn. 2010 Dec;6(4):243-51
pubmed: 20610466
Int J Soc Psychiatry. 2017 Dec;63(8):763-772
pubmed: 29067837
Am J Psychiatry. 2018 Aug 1;175(8):765-773
pubmed: 29621900
JAMA Psychiatry. 2013 Sep;70(9):913-20
pubmed: 23824214
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
BMC Psychiatry. 2016 Jul 04;16:205
pubmed: 27377549